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68 Poster Session Ihigh doseMelphalan 200 mg/M2 except 14 patients. Three patients
received Busulfan/Cytoxan/TBI (Total Body Irradiation) and 11
patients receivedMel-140/TBI. Cytogenetics studies were available
in 69/101 patients (68%). Treatment related mortality was 1% at
day 100. Complete remission was defined by negative immuno-fix-
ation. After ASCT 28/101 (28%) patients were in CR. The median
progression free survival (PFS) and overall survival (OS) was 15.6
and 50.8 months respectively. Pre and post ASCT variables (Table
1) were analyzed. Only history of prior radiation therapy (XRT) was
predictive of poor PFS and OS on univariate and multivariate anal-
ysis. Onmultivariate analysis, both status at transplant (Patients not
in CR or PR) and history of prior XRT were predictive of inferior
PFS (P 5 0.04 and\0.001, Hazard ratio of 1.6 and 3.7, respectively)
and only history of prior XRT was predictive of inferior OS (P 5
0.006, Hazard ratio of 2.5). The median time from diagnosis to
ASCTwas not influenced by history of prior therapeutic XRT.His-
tory of prior radiation therapy maintained its adverse prognostic ef-
fect independent of cytogenetics or TBI based conditioning
regimens. Complete remission post ASCTwas not predictive of im-
proved PFS or OS.
Conclusion:History of treatment with radiation therapy prior to
ASCT in AA withMM is predictive of poor PFS andOS. The cause
of the adverse impact of XRT on the outcomes after ASCT in AA
with MM is unclear at this point. This finding was unexpected
andmerits further investigation in both AA and non AAwith correl-
ative biological studies. Status at transplant of less than PR was pre-
dictive of poor outcome while CR after ASCT was not predictive of
improved PFS or OS in AA. Shorter PFS and similar OS were ob-
served in this population compared to the historical control in non
AA.184
PHASE I STUDY OF BORTEZOMIB, (BTZ) FOLLOWED BY HIGH-DOSE
MELPHALAN, (HD Mel) AND BTZ AS CONDITIONING REGIMEN FOR
TANDEM PERIPHERAL BLOOD STEM CELL TRANSPLANTS (TanPSCT)
IN PATIENTS WITH PRIMARY REFRACTORY MULTIPLE MYELOMA
(MM) AND PLASMA CELL LEUKEMIA (PCL)
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Dalton, W., Djulbegovic, B., Fernandez, H., Sullivan, D.M.,
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Background:Novel treatment approaches are paramount for pa-
tients with primary refractory MM and PCL, because despite HD
chemotherapy, patient median survival is approximately 12 months.
The proteasome inhibitor BTZ sensitizes myeloma cells to melpha-
lan both in vitro and in vivo by a mechanism not well understood. In
this study we examine the effects of BTZ, followed by BTZ andHD
Mel as conditioning regimen for TanPSCT in this poor-risk group.
Methods: Patients with primary refractory MM or PCL received 2
cycles of BTZ at 1.3 mg/m2. followed by HDMel (200 mg/m2) and
one dose of BTZ at 0.7 mg/m2, 1.0 mg/m2 or 1.3 mg/m2, as a con-
ditioning regimen prior to TanPSCT. The dose of BTZ was given
immediately after the last dose of HDMel. Bone marrow(BM) sam-
ples were collected at baseline, on day 4 and after 2 cycles of BTZ,
and at 3 months after TanPSCT, for GEP and Fanconi anemia(FA)
pathway genes assessment. Results:To date, 17 patients have been
enrolled and treated, and 11 patients are evaluable for response.Me-
dian age is 59 years (46–70) with the following myeloma distribu-
tion: 55% IgA and 45% IgG. FISH analysis showed the
following: del 13q (44%), t (4; 14) (11%), t (11; 14) (11%), trisomy
11 (11%), and polyploid (11%); standard karyotype was normal in
88% of patients and complex karyotype in 12%. Median time to
WBC engraftment (days) was 13 and 12 after the first and second
transplant, respectively. Median time to plt engraftment (days)
was 20 and 17, after the first and second transplant, respectively.
There were no dose limiting toxicities. Observed grade 3 toxicities
were related to the conditioning regimen and similar to those ob-
served with HDMel alone. One patient developed diffuse alveolar
hemorrhage after the first cycle of BTZ, which resolved, but was re-
moved from study. After 2 cycles of BTZ, 45% of patients achieved
PR, and 55% had stable disease. Overall response rate at 3 monthsfrom the second transplant increased to 90%(CR5 36%, VGPR5
27% andPR5 27%). Only 1 patient developed progressive disease
after the first transplant. Evaluations of BM samples byGEP and FA
pathway gene expression are underway. Conclusions: Single agent
BTZ induced responses in 45% and the combination of HD Mel
and BTZ as conditioning regimen for TanPSCT was well tolerated
and improved response rates to 90%. These early results suggest
that this regimen is very active in this poor-risk group. A Phase II
study is underway.185
EFFICIENT STEM CELL MOBILIZATION IN LENALIDOMIDE TREATED
MULTIPLE MYELOMA PATIENTS CAN BE ACHIEVED BY MOBILIZATION
WITH DCEP (DEXAMETHASONE, CYCLOPHOSPHAMIDE, ETOPOSIDE,
CISPLATINUM) FOLLOWED BY HIGH-DOSE G-CSF
Badin, S.M.1, Lendvai, N.2, Gounder, S.K.1, Rowley, S.2, Donato, M.2,
Goldberg, S.2, Pecora, A.2, McBride, L.H.2, Schmidt, L.2,
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High dose chemotherapy with autologous stem cell rescue
(ASCT) remains a standard therapy for multiple myeloma patients
who can tolerate it. Lenalidomide in combination with dexametha-
sone has emerged as a highly effective oral induction regimen. Con-
sequently, an increasing number of patients are receiving this
therapy prior to undergoing ASCT. However, patients treated
with lenalidomide were recently reported to have had significantly
reduced stem cell yield upon mobilization with G-CSF alone1.
We report our experience with patients treated with lenalidomide
who subsequently underwent stem cell mobilization at our institu-
tion since 2006. Our goal for collection is 10–12 106 CD341 cells
to allow for two-three transplants using at least 4 106 CD341 cells
per transplant. Our experience with patients who received lenalido-
mide-based therapy and then underwent mobilization with high
dose G-CSF (n 5 5) confirmed the above observation. The mean
yield was 6  106 CD341 cells, with only 1 of 5 patients reaching
the mobilization goal. In contrast, patients treated with lenalido-
mide-based therapy but mobilized with DCEP chemotherapy and
high dose G-CSF (n5 9) had significantly higher CD341 cell yield
and required shorter pheresis. This group’s mean yield was 26.1 
106 CD341 cells, all 9 patients reached themobilization goal of.10
 106 CD341 cells, 3 of the patients were pheresed for 1 day and 4
patients were pheresed for 2 days.
We have previously reported DCEP to be well tolerated, and
have predictable kinetics regarding initiation of collection of stem
cells. Our regimen, which can be administered on an outpatient ba-
sis, consists of 40 mg dexamethasone IV over 15 minutes  4 days,
cyclophosphamide 500 mg/m2, etoposide 40 mg/m2 (capped at 75
mg), and cisplatin 15 mg/m2 (capped at 25 mg), all continuous IV
infusions over 24 h  4 days, with G-CSF starting 24–48 h after
completion of chemotherapy, administered SQ at 5 mcg/kg  6
days followed by 10 mcg/kg daily until pheresis is completed.
In conclusion, this regimen is highly efficacious, offers excellent
stem cell yields and predictable collection kinetics, in patients
treated with lenalidomide-based therapy prior to ASCT.
1Kumar S. et al. Impact of lenalidomide therapy on stem cell mo-
bilization and engraftment post-peripheral blood stem cell trans-
plantation in patients with newly diagnosed myeloma. Leukemia.
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BORTEZOMIB ADDED TO HIGH-DOSE CYCLOPHOSPHAMIDE DURING
STEM CELL MOBILIZATION IS SAFE AND PROVIDES EFFECTIVE DISEASE
CONTROL IN CHEMOTHERAPY-REFRACTORY MULTIPLE MYELOMA
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